Shenzhen Kangzhe, a Subsidiary of China Medical System, Listed in “Shenzhen Top 500 Enterprises”

Company News

On September 25th, the list of “2023 Shenzhen Top 500 Enterprises” was officially announced. With outstanding performance in terms of overall scale, operating efficiency, creative capabilities and other comprehensive strengths, Shenzhen Kangzhe Pharmaceutical Co., Ltd. (“Shenzhen Kangzhe”), a wholly-owned subsidiary of China Medical System Holdings Limited (“CMS” or the “Group”) was once again selected, ranking 143rd on the list. Shenzhen Kangzhe was also listed on the “Top 100 Social Contribution List of 2023 Shenzhen Top 500 Enterprises”.

The “2023 Shenzhen Top 500 Enterprises” list is jointly released by the Shenzhen Enterprise Federation and Shenzhen Entrepreneurs’ Association. It is one of the most influential and authoritative rankings for Shenzhen enterprises. The list primarily evaluates participating companies based on various production and operation indicators where all the listing companies are the backbone of Shenzhen’s economic and social development.

Due to Shenzhen’s rapid economic growth and the Group’s solid operational achievements, Shenzhen Kangzhe has been selected into the “Shenzhen Top 500 Enterprises” list for several consecutive years. In the future, Shenzhen Kangzhe will continue to fulfill the Group’s mission of providing competitive products and services to meet unmet medical needs, continuously enhance its comprehensive strength, and contribute to the “quality and increment” of Shenzhen’s economic development.